Navigation Links
Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs
Date:9/15/2008

FAIRFAX, Va.ATTRACTthe first major national trial of a catheter-based treatment for deep vein thrombosiswill evaluate the use of clot-dissolving drugs in combination with clot removal devices to prevent post-thrombotic syndrome in patients with DVT (the formation of a blood clot in a leg vein). PTS, a common irreversible complication of DVT, causes permanent damage to the veins, resulting in debilitating chronic leg pain, swelling, fatigue and/or skin ulcers. About 25�� percent of DVT patients develop PTS when treated with blood thinners alone. While early treatment with blood thinners is important to prevent a life-threatening pulmonary embolism, blood thinners alone do not dissolve the existing clot, which remains in the leg. Preliminary studies have shown that interventional clot-busting treatments canunlike standard DVT therapyremove clots and have strong potential to prevent PTS. The outcomes of this pivotal multicenter trialto be funded at more than $10 million by the National Institutes of Health's National Heart, Lung and Blood Institute (NHLBI)are likely to change the way DVT is treated in the United States.

"The ATTRACT trial could fundamentally shift the 50-year-old DVT treatment paradigm to one that includes interventional clot removal as an essential element of standard DVT care," said interventional radiologist Suresh Vedantham, M.D., who will lead the trial. "By funding this study, the NHLBI has clearly recognized the strong potential of interventional radiology clot removal treatments for DVT to improve public health," added the associate professor at the Washington University School of Medicine's Mallinckrodt Institute of Radiology in St. Louis, Mo.

ATTRACT (Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis) is a multicenter, randomized trial "that will definitively determine if the newest clot-busting treatment (pharmacomechanical catheter-directed thrombolysis or PCDT) prevents post-thrombotic syndrome in patients with DVT," said Vedantham. PCDT combines the use of a clot-dissolving drug with a catheter-mounted miniature clot removal device, allowing an interventional radiologist to break up the clot and remove it from the vein, restoring blood flow. "PTS is a serious complication of DVT that is under recognized and potentially preventable if we are able to dissolve the clots early, before permanent damage to the vein occurs," he noted. "Established PTS is a lifelong, irreversible condition for which there are no consistently effective treatments. Its prevention is extremely important; however, physicians have historically neglected the prevention of PTS," said Vedantham. "The groundbreaking combination of clot-busting drugs with innovative device technologypioneered by interventional radiologistsnow enables clot removal in a safer and more efficient manner, often in a single procedure session. These advances will greatly increase the use of interventional DVT treatments," added Vedantham.

"This research is critical. The Society of Interventional Radiology Foundation initiated a DVT research consensus panel four years ago, bringing together clinicians and scientists from all disciplines and from all settingsacademia, private practice, government and industryand determining the need for the ATTRACT trial," said Michael Darcy, M.D., chair of the board of directors for SIR Foundation, a scientific foundation dedicated to fostering research and education in interventional radiology. The SIR Foundation has been a critical partner in developing the ATTRACT trial, helping to coordinate the site selection process and partnering with the ATTRACT research team to conduct the trial, said Vedantham.

DVT is the formation of a blood clot, known as a thrombus, in a deep leg vein. This can be a very serious condition that often causes permanent damage to the leg, known as post-thrombotic syndrome. Early treatment with blood thinners is important to prevent a life-threatening pulmonary embolism, but blood thinners do not dissolve the existing clot, which remains in the leg. While many patients' clots will slowly dissolve over time, often the vein wall and vein valves become irreversibly damaged in the process. "PTS develops as a direct result of having the blood clot stay in the vein. The blood clot continues to block the vein and permanently damages its one-way valves, resulting in the pooling of blood in the leg, chronic leg pain, swelling and fatigue and sometimes skin ulcers. It's logical that immediate clot removal will prevent PTS," said Vedantham.

The ATTRACT trialthe first NIH-funded multicenter, randomized trial of any interventional DVT therapywill begin later this year. The trial will assess the presence and severity of PTS, quality of life, relief of pain and swelling, safety and costs. At least 28 U.S. clinical centers will enroll 692 patients and monitor their health for two years, said Vedantham, who is chair of the DVT Research Committee of SIR's Venous Forum and vice chair of the Venous Disease Coalition. The Society of Interventional Radiology is a member of the Venous Disease Coalition.


'/>"/>

Contact: Maryann Verrillo
mverrillo@SIRweb.org
703-460-5572
Society of Interventional Radiology
Source:Eurekalert

Related biology news :

1. Wolves find happy hunting grounds in Yellowstone National Park
2. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
3. ESMO International Symposium on Immunology
4. Story tips from the US Department of Energys Oak Ridge National Laboratory, September 2007
5. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
6. Director of National Intelligence to Speak at Conference
7. Singapore National Science and Technology Awards
8. Conservation International and Toyota partner to protect Philippines rain forests
9. International team shows mercury concentrations in fish respond quickly to increased deposition
10. International team shows mercury concentrations in fish respond quickly to increased deposition
11. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
(Date:1/20/2016)... Calif. , Jan. 20, 2016  Synaptics ... of human interface solutions, today announced sampling of ... solution for wearables and small screen applications including ... as printers. Supporting round and rectangular shapes, as ... offers excellent performance with moisture on screen, while ...
(Date:1/15/2016)... SAN JUAN, Puerto Rico , Jan. 15, 2016 ... forcing companies big and small to find new ways ... data driven culture. iOS and ... their device based on biometrics, transforming it into a ... can request that users swipe their fingerprint on their ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... February 11, 2016 ... or "Company") (OTCQB: PSID), a life sciences company ... its Thermomedics subsidiary, which markets the Caregiver® FDA-cleared ... plan in January 2016, including entering into agreements ... monthly sales growth, and establishing several near-term pipeline ...
(Date:2/11/2016)... ... February 11, 2016 , ... Global ... new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to distribute exosome injection ... American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El ...
(Date:2/10/2016)... 10, 2016 Early-career researchers from ... Peru , Uganda and Yemen ... health and nutrition   Indonesia , ... and Yemen are being honored for their ... are also celebrated for mentoring young women scientists who are pursuing careers ...
(Date:2/10/2016)... , Feb.10, 2016 ASAE is introducing ... Association Management Companies (AMC) the option of joining or ... annual fee determined by staff size, every employee in ... join ASAE and reap all available member benefits.   ... "Our new organizational membership options will allow organizations of ...
Breaking Biology Technology: